Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal AC conjugate vaccine
- Development stage
- Approved
- Lead developer
- Sanofi Pasteur
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **meningococcal AC conjugate vaccine** is a sterile, non-live, inactivated conjugate vaccine designed to induce immunity against invasive diseases caused by Neisseria meningitidis serogroups A and C (and commonly also W and Y, depending on the formulation)[1][4][7][9]. It uses specific polysaccharide antigens from the bacterial capsule, chemically conjugated to a carrier protein (such as diphtheria toxoid), to elicit a strong T-cell dependent immune response and long-lasting protective antibodies[1][7]. This vaccine is primarily indicated for the prevention of meningococcal meningitis and septicemia in children, adolescents, and adults at increased risk, including as part of national immunization programs[1][4][7]. Multiple branded formulations exist, such as Menactra (licensed by Sanofi), Menveo (GSK), MenQuadfi (Sanofi), and Nimenrix (Pfizer)[7]. It does not protect against all serogroups (not serogroup B).
- Brand names
- MenactraMenveoMenQuadfiNimenrix
- Other names
- MenACWY vaccinemeningococcal conjugate vaccinemeningococcal diphtheria conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal AC conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal AC conjugate vaccine.